Sensitive methods for the detection of an insertion in exon 20 of the HER2 gene in the metastasis of non‑small cell lung cancer to the central nervous system

Krawczyk,Paweł; Nicoś,Marcin; Powrózek,Tomasz; Mlak,Radosław; Sawicki,Marek; Jarosz,Bożena; Pająk,Beata; Kucharczyk,Krzysztof; Stencel,Dariusz; Trojanowski,Tomasz; Milanowski,Janusz

doi:10.3892/ol.2013.1495

October 2013 Volume 6 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

October 2013 Volume 6 Issue 4

Full Size Image

Article

Sensitive methods for the detection of an insertion in exon 20 of the HER2 gene in the metastasis of non‑small cell lung cancer to the central nervous system

Authors:
- Paweł Krawczyk
- Marcin Nicoś
- Tomasz Powrózek
- Radosław Mlak
- Marek Sawicki
- Bożena Jarosz
- Beata Pająk
- Krzysztof Kucharczyk
- Dariusz Stencel
- Tomasz Trojanowski
- Janusz Milanowski
View Affiliations / Copyright

Affiliations: Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Lubin 20-954, Poland, Department ofThoracic Surgery, Medical University of Lublin, Lubin 20-954, Poland, Department of Neurosurgery and Pediatric Neurosurgery, Medical University of Lublin, Lubin 20-954, Poland, BioVectis Ltd., Kucharczyk TE, Warsaw 02-106, Poland, Boehringer Ingelheim Poland, Warsaw 02-675, Poland
Pages: 1063-1067
|
Published online on: July 26, 2013

https://doi.org/10.3892/ol.2013.1495
Expand metrics +

Abstract

The HER2 (ErbB2/neu) protein is a member of the HER (ErbB) receptor family (EGFR, HER2, HER3 and HER4) that expresses tyrosine kinase activity in the intracellular domain. EGFR and HER2 overexpression is observed in numerous types of cancer, nevertheless, the susceptibility of patients with non‑small cell lung cancer (NSCLC) to therapy with EGFR and HER2 tyrosine kinase inhibitors (TKIs) depends on mutations present in the respective coding genes (driver mutations). In the present study, PCR and amplified DNA fragment length analysis (FLA) were used along with the multi‑temperature single‑strand conformation polymorphism (MSSCP) technique in order to identify the 12 base pair insertion in exon 20 of the HER2 gene in 143 patients with NSCLC metastasis to the central nervous system. The prevalence of the HER2 gene mutation was correlated with mutations in the EGFR and BRAF genes. The insertion in exon 20 of the HER2 gene was observed in a single 77‑year‑old, non‑smoking male, with poorly‑differentiated adenocarcinoma of the lung (1.5% of adenocarcinoma patients). No other genetic abnormalities were identified in this patient. In the therapy of NSCLC patients with HER2 gene mutations, drugs that inhibit the EGFR and HER2 receptors, for example afatinib, may be effective. The identification of other driving mutations in NSCLC cells appears to be key to the appropriate qualification of molecular targeted therapies.

View Figures

View References

1	Hirsch FR, Varella-Garcia M and Cappuzzo F: Predictive value of EGFR and HER2 overexpression in advanced non-small lung cancer. Oncogene. 28:32–37. 2009. View Article : Google Scholar : PubMed/NCBI
2	Sun M, Behrens C, Feng L, et al: HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res. 15:4829–4837. 2009. View Article : Google Scholar : PubMed/NCBI
3	Mounawar M, Mukeria A, Le Calvez F, et al: Patters of EGFR, HER2, TP53, and KRAS mutation of p14arf expression in non-small lung cancer in relation to smoking history. Cancer Res. 67:5667–5672. 2007. View Article : Google Scholar : PubMed/NCBI
4	Pao W and Girard N: New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011. View Article : Google Scholar : PubMed/NCBI
5	Shigematsu H, Takahashi T, Nomura M, et al: Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 65:1642–1646. 2005. View Article : Google Scholar : PubMed/NCBI
6	Sasaki H, Shimizu S, Endo K, et al: EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer. 118:180–184. 2006. View Article : Google Scholar : PubMed/NCBI
7	Buttitta F, Barassi F, Fresu G, et al: Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer. 119:2586–2591. 2006. View Article : Google Scholar : PubMed/NCBI
8	Stephen P, Hunter C, Bignell G, et al: Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature. 431:525–526. 2004. View Article : Google Scholar : PubMed/NCBI
9	Wang SE, Narasanna A, Perez-Torres M, et al: HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell. 10:25–38. 2006. View Article : Google Scholar : PubMed/NCBI
10	Li C, Fang R, Sun Y, et al: Spectrum of oncogenic driver mutations in lung adenocarcinomas from east asian never smokers. PLoS One. 6:e282042011. View Article : Google Scholar : PubMed/NCBI
11	Kaczanowski R, Trzeciak L and Kucharczyk K: Multitemperature single-strand conformation polymorphism. Electrophoresis. 22:3539–3545. 2001. View Article : Google Scholar : PubMed/NCBI
12	Sanger F, Nicklen S and Coulson AR: DNA sequencing with chain terminating inhibitors. Proc Natl Acad Sci. 74:5463–5467. 1977. View Article : Google Scholar : PubMed/NCBI
13	Diaz R, Nguewa PA, Parrondo R, et al: Antitumor and angiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model. BMC Cancer. 10:188–197. 2010. View Article : Google Scholar : PubMed/NCBI
14	Shimamura T, Ji H, Minami Y, et al: Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res. 66:6487–6491. 2006. View Article : Google Scholar : PubMed/NCBI
15	Reid A, Vidal L, Shaw H and de Bono J: Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer. 43:481–489. 2007. View Article : Google Scholar : PubMed/NCBI
16	Li D, Ambrogio L, Shimamura T, et al: BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 27:4702–4711. 2008. View Article : Google Scholar : PubMed/NCBI
17	Perera SA, Li D, Shimamura T, et al: HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci USA. 106:474–479. 2009. View Article : Google Scholar : PubMed/NCBI
18	Shimamura T, Greulich H, Solca FF and Wong KK: Efficacy of BIBW-2992, potent irreversible inhibitor of EGFR and HER2 in human NSCLC xenografts in a transgenic mouse lung-cancer model: C7–04. J Thorac Oncol. 2(suppl): S3802007.
19	Hirsh V: Afatinib (BIBW 2992) development in non-small-cell lung cancer. Future Oncol. 7:817–825. 2011. View Article : Google Scholar : PubMed/NCBI
20	De Greve J, Teugels E, De Mey J, et al: Clinical activity of BIBW2992, an irreversible inhibitor of EGFR and HER2 in adenocarcinoma of the lung with mutations in the kinase domain of HER2neu. J Thorac Oncol. 4:S307(abstr). 2009.PubMed/NCBI
21	Heinmöller P, Gross C, Beyser K, et al: HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin. Clin Cancer Res. 9:5238–5243. 2003.PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Sensitive methods for the detection of an insertion in exon 20 of the HER2 gene in the metastasis of non‑small cell lung cancer to the central nervous system

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles